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ABSTRACT
Characterization of the Role Nuclear Bmp2 (nBmp2) Plays
in Regulating Gene Expression
Fialka Grigorova
Department of Microbiology and Molecular Biology, BYU
Master of Science
The nBmp2 protein was first identified in a DNA affinity chromatography/mass
spectrometry screen designed to detect proteins that interact with a cartilage-specific
enhancer element (called D/E) from the type XI collagen gene Col11a2. The
transcription factor SOX9, a protein from the Sox (SRY-related HMG box) family, binds
to and activates gene expression from this enhancer. nBmp2 has no transcriptional
activity of its own on this enhancer, but when co-transfected with SOX9 it increases
SOX9’s activation of D/E nearly 2-fold. SOX9 also activates cartilage-specific enhancer
elements from the Col2a1, Col27a1, and Col9a1 genes. The purpose of this project was
to determine 1) whether nBmp2 similarly effects SOX9-dependent expression from these
enhancers, and 2) whether it does so by binding (either directly or indirectly) to the
Col2a1, Col27a1, and Col9a1 enhancers. The work described in this thesis has shown
that nBmp2 increases luciferase levels produced from three enhancer/reporter plasmids,
but it does so without binding directly to the enhancers. This work has opened up a new
area of exploration into the function of the novel protein nBmp2 to examine its potential
effects on a variety of different gene regulatory processes.
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Introduction
nBmp2
Bone morphogenetic proteins (BMPs) are secreted signaling molecules of the
transforming growth factor beta (TGF beta) superfamily (Ducy and Karsenty
2000; Mishina 2003). They were first identified as proteins that play a central role in
developmental processes, especially in cartilage and bone formation. More than thirty
BMP family members are acknowledged to date. Bmp2 is involved in bone formation
(Wozney, Rosen et al. 1988; Hogan 1996; Ducy and Karsenty 2000; Lories and Luyten
2005). Bmp2 also plays a critical role in cardiac cushion formation and in the epithelialmesenchymal transition (Ducy and Karsenty 2000) and is involved in heart and
myocardial patterning (Zhang and Bradley 1996; Ma, Lu et al. 2005). BMP2 is also
involved in neural development (Goldstein, Brewer et al. 2005), limb patterning
(Schlange, Arnold et al. 2002) and induction of osteoblast differentiation (Reddi,
Muthukumaran et al. 1989; Luyten, Cunningham et al. 1992) .
Recently in Dr. Bridgewater’s laboratory, Jenny Felin and others demonstrated
the presence of a nuclear form of Bmp2 (nBmp2) in several different cell lines (Fig. 1)
(Felin, Mayo et al. 2010). Previously, BMP2 was recognized only as a secreted growth
factor derived from a pro-protein that undergoes cleavage to release the mature protein
from the propeptide while it passes through the secretory pathway. Mutational analyses
showed that translation of nBmp2 is initiated from a downstream alternative start codon
to generate a protein that lacks the N-terminal signal peptide and is thus translated in the
cytoplasm rather than the endoplasmic reticulum. This protein contains a nuclear
1

localization signal (NLS) that overlaps the cleavage site, which directs translocation of
the uncleaved nBmp2 to the nucleus (Fig.2) (Felin, Mayo et al. 2010).
SOX 9 transcription factor
Gene transcription is a complex process involving many elements that work
together to appropriately activate and transcribe a gene. Transcription factors bind to
DNA and interact with the promoter to regulate gene expression. Activators and
repressors are specific transcription factors. They can activate or repress the transcription
of individual genes (Nelson 2000).
Activators bind to enhancer or cis-acting elements and increase gene expression
by inducing conformational changes. Enhancers have one or more consensus sequences
to which activators can bind. These enhancer elements in DNA can be located upstream,
downstream, or in a transcriptional entity (Nelson 2000). When the DNA is ready for
transcription, the enhancer sequences become available for activator proteins to bind.
These interactions between transcription factors, co-activators and the RNA Pol II
complex initiate transcription (Carey 1999).
Most SOX proteins are transcription factors that are involved in pre-B and T cell
development, sex determination, neural induction, and skeletal formation (Mertin,
McDowall et al. 1999). SOX9 is one of the SOX proteins that regulates cartilage collagen
(Col) genes by binding to the enhancer element regions of these genes (Lefebvre, Huang
et al. 1997; Bridgewater, Lefebvre et al. 1998; Zhou, Lefebvre et al. 1998; Liu, Li et al.
2000; Lefebvre, Behringer et al. 2001; Bridgewater, Walker et al. 2003; Zhang, Jimenez
2

et al. 2003).
SOX9 also is expressed in brain and testis cells and activates the anti-Mullerian
hormone (AMH) gene (Mertin, McDowall et al. 1999; Harley, Clarkson et al. 2003; Stolt,
Lommes et al. 2003). Campomelic dysplasia (CD) is caused by haploinsufficiency of
SOX9 protein in human. It is a fatal disease characterized by XY sex reversal and
endochondral bone malformation (Huang, Zhou et al. 2000; Harley, Clarkson et al.
2003; Mori-Akiyama, Akiyama et al. 2003). Patients with CD have impaired gonadal and
skeletal development because either the anti-Mullerian hormone gene or other genes that
exist downstream of SOX9 are not sufficiently activated (Huang, Zhou et al. 2000).
As mentioned before, SOX9 is a member of Sox (SRY-related HMG box)
superfamily, with high mobility group (HMG) domain that helps them to bind DNA. Sox
proteins share >50% of similarity with the HMG domain of SRY (sex determining factor)
(Harley, Clarkson et al. 2003). In SOX9 protein, the HMG domain has three α-helices
that form a twisted L-shaped supported by a hydrophobic core. Sox9 protein binds to the
minor groove of DNA by its consensus sequence which is heptameric
(A/T)(A/T)CAA(A/T)G. After binding to DNA, it induces bending and conformational
changes in the RNA Pol II complex, which causes unwinding of DNA and initiating
transcription (Wegner 1999; Dailey and Basilico 2001). When the cyclic AMP-dependent
protein kinase (PKA) phosphorylates SOX9, it increases SOX9’s transcriptional activity
(Huang, Zhou et al. 2000).
SOX9 protein, like SOX8 and SOX10 proteins, has an HMG domain, at least one
transactivation domain, and a dimerization domain. Removing the PQS transactivation
3

domain of these proteins causes transcription reduction. The transcription activation
domain of the SOX9 is located at the C terminus of the protein. It cooperates directly or
indirectly with the Pol II complex. In addition to PQS domain, only SOX9 has another
domain, PQA. However, all these proteins, SOX9, SOX8 and SOX10, have dimerization
domains that help binding between these proteins forming DNA-dependent heterodimers
and homodimers (Sudbeck, Schmitz et al. 1996; Bernard, Tang et al. 2003; Sock, Pagon
et al. 2003).
Dimerization of SOX9 is required for its function as a transcriptional activator
protein in cartilage genes. However, SOX9 binds as a monomer in sex determination
gene regulation (Bernard, Tang et al. 2003). As mentioned before, dimerized SOX9
controls the regulation of some cartilage collagen genes (Col2a1, Col11a2, Col9a2,
Col27a1, and CD-RAP) by binding to the enhancer element regions of these genes. The
enhancer elements in these genes contain SOX9 sites paired in opposite orientation to
each other with three base pairs in between (Lefebvre, Huang et al. 1997; Bridgewater,
Lefebvre et al. 1998; Zhou, Lefebvre et al. 1998; Liu, Li et al. 2000; Lefebvre, Behringer
et al. 2001; Bridgewater, Walker et al. 2003; Zhang, Jimenez et al. 2003).
Cartilage-specific collagen genes and their enhancers
Type II collagen (Col2a1) is a homotrimeric molecule that contains three α1(II)
chains. It is the core component of cartilage collagen fibrils. Collagen fibrils are a
fundamental part of the interactions of proteins in the extracellular matrix of the cartilage.
Type II collagen, after post-translational modification, contacts other triple-helical
collagen genes (Col9a1 and Col11a1) to form fibrils (Zhang et al., 2003).
4

In the published article where the 48-bp Col2a1 cartilage-specific enhancer was
first identified, the author identified SOX9 binding sites in a 48-base pair enhancer from
the Col2a1 gene (Lefebvre, Zhou et al. 1996). These sites are required for chondrocytespecific enhancer activity in transgenic mice and transient transfections. Dimeric SOX9
binds at these paired sites that are directed in opposite orientation to each other with three
base pairs in between. Mutations in any of the SOX9 sites inhibited chondrocyte-specific
expression of reporter genes in transgenic mice and in transiently transfected cells. That
shows that dimerized SOX9 plays an essential role in Col2a1 gene activation (Zhou,
Lefebvre et al. 1998; Dailey and Basilico 2001).
Type XXVII collagen (Col27a1) is a minor fibrillar collagen. It is highly
expressed in cartilage and weakly expressed in the ear, eye, lung, and colon tissues
(Cheah, Lau et al. 1991; Tsumaki, Kimura et al. 1996; Tsumaki, Sugimoto et al.
1996; Pace, Corrado et al. 2003). Jenkins et al. (2005) demonstrated that Col27a1 has at
least two similar enhancer elements that bind SOX9 at paired sites. Mutations in any of
the sites or changing the spacing between the sites disabled enhancer function (Jenkins,
Moss et al. 2005).
Type IX collagen is a heterotrimeric molecule like type II and type XI collagens.
It is composed of the Col9a1, Col9a2, and Col9a3 gene products. Its function in the inner
part of the fibril is to limit the fibril diameter as well as stabilize cartilage collagen fibrils.
An enhancer from the Col9a1 gene was identified, which contains four separate SOX9binding sites. The sites are arranged as two pairs with each pair resembling those in the
Col27a1 and Col2a1 enhancers, but in this case, all four sites are required for enhancer
5

activity. All four sites bind SOX9, and mutation of any one of the four sites abolished
enhancer activity (Zhang, Jimenez et al. 2003; Genzer and Bridgewater 2007).
Rationale for this project
The nBmp2 protein was first identified in a DNA affinity chromatography/mass
spectrometry screen designed to detect proteins that interact with a cartilage-specific
enhancer element (called D/E) from the type XI collagen gene Col11a2. The
transcription factor SOX9 binds to and activates gene expression from this enhancer.
Another student in our lab, Brandt Nichols, recently performed reporter assays which
demonstrated that although nBmp2 has no transcriptional activity of its own, when cotransfected with SOX9, it increases SOX9’s activation of the D/E enhancer, and of two
other Col11a2 enhancers, as much as 2-fold. Since SOX9 also activates cartilagespecific enhancer elements from the Col2a1, Col27a1, and Col9a1 genes, this project
focused on those enhancers. The purpose of this project was to determine 1) whether
nBmp2 similarly effects SOX9-dependent expression from these enhancers, and 2)
whether it does so by binding directly to the Col2a1, Col27a1, and Col9a1 enhancers.
The results show that nBmp2 increases SOX9-regulated reporter gene expression
from the Col27a1 27C/D/E and 27F/G enhancers and the Col9a1 M1/M2/D1/D2
enhancer. It does not, however, act as a transcription activator by itself.
Electrophoretic Mobility Shift Assay (EMSA) experiments revealed that even
though nBMP2 increases SOX9-dependent gene expression, it does not bind directly to
the enhancer DNA sequences. It is possible, then, that nBmp2 increases reporter gene
6

expression by binding indirectly to SOX9 or perhaps by post-transcriptional mechanisms
such as stabilizing mRNA or inhibiting protein degradation.
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Methods
Cell types and culture
Human embryonic kidney (HEK293) cells were cultured at 37°C with 5% CO2 in
supplemented Dulbecco’s modified Eagle medium nutrient mixture F-12 HAM (D-MEM
F-12) (Gibco). Supplemented medium contained 10% Fetal Bovine Serum
(FBS)(HyClone). Cells were passaged at approximately 90% confluence by using
(0.05%) trypsin (HyClone) every 3-4 days but not used after passage 25.
Plasmids
The reporter plasmids were all constructed and described previously (Jenkins, E.,
J. B. Moss, et al. 200; Genzer, M. A. and L. C. Bridgewater 2007; Zhou, G., V. Lefebvre,
et al. 1998). In every case, the enhancer reporter constructs included four tandem copies
of the enhancer of interest (see sequences in Table 1) upstream of a minimal promoter
that was derived from the Col2a1 gene but that has no transcriptional activity in the
absence of an enhancer element. These elements controlled a firefly luciferase reporter
plasmid. The SOX9-pCDNA-5’-UT plasmid was constructed in the lab of Dr. Benoit de
Crombrugghe and has been described previously (Zhou, G., V. Lefebvre, et al. 1998).
The nBmp2 expression plasmid was constructed for this study by cloning a 5’ truncation
of the Bmp2 cDNA into the expression vector pcDNA3.1(+). The 5’ truncation removed
all sequence upstream of the alternative start codon that produces nBmp2, so the
construct is not capable of producing secreted Bmp2. The internal control for
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transfection efficiency, pRL, expresses renilla luciferase constitutively and was
purchased from Promega.
Enhancer/reporter assays
Transfections were performed in duplicate or triplicate. Briefly, ~ 300,000 cells
were seeded to each well of 6-well plates and incubated at 37°C with 5% CO2 in
supplemented Dulbecco’s modified Eagle medium nutrient mixture F-12 HAM and
grown to a confluence of at least 70%. Then 2µg of plasmid DNA (enhancer/firefly
luciferase reporter plasmid (1µg), pRL4 constitutive renilla luciferase expression vector
as an internal control for transfection efficiency (0.33 µg), the SOX9 expression vector
SOX9-pcDNA-5’-UT (0 or 0.33 µg), the nBmp2 expression plasmid nBMP2-pcDNA-5’UT (0 or 0.33 µg), and/or the empty vector pcDNA3.1 (0, 0.33 or 0.66 µg) was added to
100 µL OPTI-MEM® I plus 6 µL PLUS reagent and allowed to form complexes for 15
minutes at room temperature.
Meanwhile, 100 µL OPTI-MEM® I plus 4 µL LipofectamineTM were mixed for
each sample. After the incubation, diluted Lipofectamine was added to the DNA/PLUS
complexes and incubated for 15 minutes at room temperature. During this incubation, the
old medium was removed from each well and 2 ml Opti-MEM was added into each well.
Finally, the DNA/PLUS/Lipofectamine complexes were added dropwise to the cells and
mixed gently. Then, after 6 hours, 200µL (100%) FBS was added to a final concentration
of 10% FBS. Transfected cells were incubated at 37oC with 5% CO2 for 20-24 hours
and then again the old medium was removed from each well and fresh 2ml 10% FBS
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media was added to the wells. Transfected cells were allowed to grow for a total of 40-48
hours before being analyzed.
Cell extracts were prepared 40-48 h after the transfection, and enzyme activity
assays were performed. First, cells were rinsed (1x) with 2mL 1xPBS (room temperature)
and then the Dual Luciferase Assay System (Promega) was used to measure the firefly
and Renilla luciferase activity, according to the manufacture’s instruction.
Briefly, 100 µL Luciferase Assay Reagent as a substrate was combined with 20
µL cell extract. Results were measured in a TD 20/20 luminometer (Turner Designs).
Then in a short period (5 seconds) 100 µL renilla luciferase substrate was added into the
mixture. Again, results were measured in a TD 20/20 luminometer (Turner Designs).
Finally, all results were calculated as firefly luciferase (x100.000)/ renilla luciferas and
data were normalized to 100% activity for reporter plasmid with SOX9 alone. Student’s
t-test was used to analyze for statistical significance All graphs presented include data
from 4 or 5 independent experiments, each performed in duplicate or triplicate.
In Vitro Transcription/Translation
SOX9 and nBmp2 for EMSA experiments were synthesized by in vitro
transcription/translation of the SOX9-pcDNA-5’-UT SOX9 expression plasmid and the
nBmp2-pcDNA3.1 expression plasmids using the TNT Coupled Reticulocyte Lysate
System (Promega). Reticulocyte Lysate (40 µl), expression plasmid (0.5 µg), methionine,
and water to a total volume of 50 µl were mixed in a single tube and incubated at 30oC
for 90 min. The negative control did not have DNA template in the mixture. Control
10

reactions were prepared as described with the substitution of 35S-methionine for
methionine with either DNA template for SOX9 or nBmp2 or no DNA template.
Products from reaction containing 35S-methionine were separated by SDS-PAGE (10%)
and visualized using autoradiography in order to verify protein production and correct
product size (Fig. 8).
Electrophoretic mobility shift assays (EMSA)
EMSA experiments were performed using the Col9a1 (M1/M2/D1/D2) and
Col27a1 (27C/D/E and 27F/G) enhancer elements as DNA probes (for sequences, see
Table 1). 5’ GATC overhangs of each double-stranded oligonucleotide were 32P
radiolabeled by end filling with Klenow (Promega) fragment using a 32 P-dGTP and
dNTP mix (no dGTP). For binding reaction, 1 µL in vitro transcribed and translated
SOX9 and/or nBmp2 protein and 1 µL radiolabeled probe were combined in 25 µL
DNA-binding buffer (20mM Hepes (pH 7.9), 10% glycerol, 50mM KCL, 0.05% NP-40,
0.5 mM DTT and 1 mM PMSF). 0.1 µg of poly (dG-dC). poly(dG-dC) was added as a
nonspecific competitor. The mix was incubated with or without SOX9/nBmp2 antibody
at room temperature for 30 min. If antibody was included, it was pre-incubated with the
proteins and other components for 30 min before the addition of radiolabeled probes.
Binding reactions were separated by electrophoresis for 2-3h at 150V on native 8%
polyacrylamide gels. Then the gels were dried for 45min at -80 oC using a Hoefer Slab
Gel Dryer. Results were visualized by autoradiography.
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Statistical Analysis
Triplicate transient transfection results were averaged and then the averaged
results were normalized to 100% for the activity produced by SOX9 alone. The
normalized independent repeats were then averaged together and statistical significance
was determined using Student’s t- test.
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Results
nBmp2 increases SOX9-dependent reporter gene expression.
To determine whether nBmp2 effects SOX9-dependent expression from the Col27a1
(27C/D/E and 27F/G), Col9a1 (M1/M2/D1/D2), and Col2a1 (48-bp) enhancers, the
enhancer/reporter assay was performed. The results show that nBmp2 alone cannot activate the
transcription from the Col27a1, Col9a1 or Col2a1 enhancers. However, it cooperates with SOX9
to further increases transcription from the Col27a1 (27C/D/E and 27F/G) and Col9a1
(M1/M2/D1/D2) enhancer elements (Figure 4-7).
It was interesting to see that nBmp2 activates the unusual Col9a1 enhancer with
its four SOX9-binding sites. In figure 4 it shows that nBmp2 with cooperation of SOX9
in Col9a1 (M1/M2/D1/D2) enhancer element significantly increases the transcription ~16
6% SE (p=0.018) (Fig.4). The nBmp2 protein significantly increased SOX9-dependent
expression from the Col27a1 (27C/D/E) enhancer element by ~14

5% SE (p= 0.021)

(Fig.5). The nBmp2 protein also significantly increased SOX9-dependent expression
from the Col27a1 (27F/G) enhancer element by ~27

7% SE (p= 0.007) (Fig.6). In

contrast, nBmp2 did not significantly increased SOX9-dependent expression from the
Col2a1 (48-bp) enhancer element (p=0.189) (Fig.7).
nBmp2 does not bind directly to enhancer elements in EMSA experiments.
Having demonstrated that nBmp2 increases SOX9-dependent gene expression
from the Col27a1 C/D/E and F/G and the Col9a1 M1/M2/D1/D2 enhancers, we

13

performed EMSA experiments to see if nBmp2 binds along with SOX9 to these
enhancers. The sequences of the enhancer element probes are shown in Table 1.
SOX9 bound each enhancer as has been previously shown and produced a
mobility shift (Figures 9, 10 and 11, arrows) (Zhou et al., 1998; Dailey, Basilico,
2001; Jenkins et al., 2005; Zhang et al., 2003; Genzer, Bridgewater, 2007). The nBmp2
protein alone did not shift any of the enhancers, which was not surprising since it also did
not independently increase their activity in the reporter assays. It was surprising,
however, that when nBmp2 and SOX9 were co-incubated with the enhancers, the shift
produced was identical to that caused by SOX9 alone, indicating that nBmp2 does not
bind any of the enhancer elements, even in cooperation with SOX9 (Figures 9-11).
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Discussion
The SOX9-binding enhancer elements from the Col27a1, Col2a1, and Col9a1
genes were used in this project to determine whether nBmp2 plays a role in regulating the
expression of other SOX9-responsive enhancer elements besides the ones from Col11a2.
I determined that nBmp2 increases reporter gene expression when co-transfected with
SOX9 in enhancer/reporter assays with the 27C/D/E and 27F/G enhancers from the
Col27a1 gene and M1/M2/D1/D2 enhancer from the Col9a1 gene. It does not, however,
act as a transcription activator by itself. EMSA experiments were then used to determine
whether nBmp2 exerts its effect on gene expression by binding to the enhancer elements.
I expected that if nBmp2 does function as a traditional transcription factor or co-activator,
it would bind to these enhancer elements either independently or in cooperation with
SOX9. Surprisingly, the EMSA experiments reveal that nBMP2 does not bind to the
enhancer DNA sequences.
The nBmp2 protein clearly increased luciferase expression in the reporter assays,
so its failure to bind to the enhancers like a transcriptional activator or co-activator
suggests that it has post-transcriptional functions. Some possibilities that could account
for nBmp2’s ability to increase luciferase levels in our reporter assays include
stabilization of SOX9 mRNA or luciferase mRNA. A global stabilization of all mRNAs
is a less likely explanation because all results were normalized to the pRL4 renilla
luciferase control plasmid.
nBmp2 might also function by slowing degradation of SOX9 or luciferase proteins. A

yeast two-hybrid screen that was performed to obtain clues about nBmp2’s function by
15

identifying protein binding partners found that nBmp2 binds to ROC1, an E3 ubiquitin
ligase protein (unpublished data). ROC1 has several known targets including the cell
cycle inhibitory proteins p21 and p27, which it marks for degradation by the proteasome
pathway. Inactivation of ROC1 in a mouse model caused accumulation of p27, which
inhibited cell proliferation and caused embryonic death, demonstrating the critical role
that ROC1 plays in protein degradation (Jia L. et al 2009; Tsvetkov D. et al). Perhaps
nBmp2’s effect on reporter gene expression in our assays is caused by nBmp2’s
interactions with ROC1 or with other proteins in the ubiquitin/proteasome pathway.
Finally, it is possible that nBmp2 forms a complex with SOX9 that is not strong
enough to remain bound during the EMSA assay. It could participate in a complex
something like SAGA (Spt-Ada-Gcn5-acetyltrasferase), which activates transcription and
includes both a histone acetyltransferase and a ubiquitin protease. (Weake, Dyer et al.
2011).
In summary, the work described in this thesis has shown that nBmp2 increases
luciferase levels produced from three enhancer/reporter plasmids, but it does so without
binding to the enhancers. This work has opened up a whole new area of exploration into
the function of the novel protein nBmp2 to examine its potential effects on a variety of
different post-transcriptional regulatory processes.
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Table 1
Enhancer element sequence regions with SOX9 binding sites

Element

Sequence

M1/M2/D1/D2

agtgggcacatttttactggaacctca[gccctCTGAAAGcttcCACTGTAttcctata
gcagttCTGAAAGctgcCATTGTActcct]atagcagat

27C/D/E

ctccgtTTGTGTAattaAACAAAGctgCCTTTTATttctctccagggctc

27F/G

aaagacttgaagaaaaccTTCTCTGtccCTTTGAAatgctttcccagggt

48-bp

ctgtgaatcgggCTCTGTAtgcgcttgAGAAAAGcccCATTCATgaga

*brackets indicate the boundaries of the M1/M2/D1/D2 EMSA probe
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Figure 1. Endogenous Bmp2 is evident in the nuclei of three cell lines. A) 10T1/2
mesenchymal cells, BALB/3T3 fibroblast cells, and RCS cells were cultured on slides
and then immunostained using an anti-Bmp2 (green) antibody. TO-PRO-3 (red) was used
to stain the nuclei of these cells. Then the cells were examined by laser confocal
microscopy. B) Preabsorption of anti-Bmp2 antibody with recombinant human Bmp2
verified the specificity of the Bmp2 antibody.
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Figure 2. Schematic of the Bmp2 preproprotein. The rat Bmp2 preproprotein map
shows the signal peptide, propeptide, and mature chain. The arrow shows the location of
proteolytic cleavage to release the mature secreted growth factor. The bold bases indicate
the important amino acids in the bipartite NLS (Felin, Mayo et al. 2010).

19

Figure 3. Schematic diagram of the 5’ region of mouse Col11a2. The B/C and D/E
enhancers in the upstream promoter region and the F/G enhancer in the first intron are
represented as boxes, with the expanded views of each enhancer showing approximate
locations of two heptameric Sox-binding sites. (This figure was originally published by
Bridgewater et al. (Bridgewater, Walker et al. 2003)).
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*
*

Figure 4. nBmp2 increases SOX9 activation of the Col9a1 M1/M2/D1/D2
enhancer element. The M1/M2/D1/D2 enhancer/reporter plasmid was transfected
into HEK293 cells in combination with Sox9 and/or nBmp2 expression plasmids as
shown. The pRL4 renilla luciferase expression plasmid was included in each reaction
as an internal control for transfection efficiency. This figure includes data from five
independent experiments, each performed in duplicate or triplicate. The results of
each independent experiment were normalized to 100% activity for Sox9 (yellow).
The control included reporter plasmid with empty pcDNA3.1 vector, without Sox9 or
nBmp2 (gray). *(p=0.018)
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*
*

Figure 5. nBmp2 increases SOX9 activation of the Col27a1 C/D/E enhancer
element. The 4x27(C/D/E) enhancer/reporter plasmid was transfected into HEK293 cells
in combination with Sox9 and/or nBmp2 expression plasmids as shown. The pRL4
renilla luciferase expression plasmid was included in each reaction as an internal control
for transfection efficiency. This figure includes data from six independent experiments,
each performed in duplicate or triplicate. The results of each independent experiment
were normalized to 100% activity for Sox9 (yellow). The control included reporter
plasmid with empty pcDNA3.1 vector, without Sox9 or nBmp2 (gray). *(p= 0.021)
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*

*

Figure 6. nBmp2 increases SOX9 activation of the Col27a1 F/G enhancer element.
The 4x27(F/G) enhancer/reporter plasmid was transfected into HEK293 cells in
combination with Sox9 and/or nBmp2 expression plasmids as shown. The pRL4 renilla
luciferase expression plasmid was included in each reaction as an internal control for
transfection efficiency. This figure includes data from four independent experiments,
each performed in duplicate or triplicate. The results of each independent experiment
were normalized to 100% activity for Sox9 (yellow). The control included reporter
plasmid with empty pcDNA3.1 vector, without Sox9 or nBmp2 (gray). *(p= 0.007)
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Figure 7. nBmp2 has no effect on SOX9 activation of the Col2a1 48-bp enhancer
element. The 4x48-bp enhancer/reporter plasmid was transfected into HEK293 cells
in combination with Sox9 and/or nBmp2 expression plasmids as shown. The pRL4
renilla luciferase expression plasmid was included in each reaction as an internal
control for transfection efficiency. This figure includes data from six independent
experiments, each performed in duplicate or triplicate. The results of each
independent experiment were normalized to 100% activity for Sox9 (blue). The
control included reporter plasmid with empty pcDNA3.1 vector, rather than Sox9 or
nBmp2 (green). *(p=0.189)
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pcDNA 3.1 nBMP2 used for EMSA

pcDNA 3.1 SOX-9 used for EMSA

Blank (no template)

Protein Marker

Figure 8. In vitro transcription/translation of the SOX9 and nBmp2. Proteins for
EMSAs were synthesized in vitro from the SOX9-pcDNA-5’-UT SOX9 expression
plasmid and the nBmp2-pcDNA3.1 expression plasmids using the TNT Coupled
Reticulocyte Lysate System (Promega). Radiolabeled methionine was incorporated into a
small parallel reaction with each plasmid to confirm protein synthesis by visualization of
the protein after SDS-PAGE separation. Both SOX9 (~60 kDa) and nBmp2 (~38 kDa)
were synthesized successfully.
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Figure 9. nBmp2 does not bind to the Col9a1 M1/M2/D1/D2 enhancer in
EMSA. The Col9a1 M1/M2/D1/D2 enhancer was radiolabeled by end-filling and
incubated with proteins as indicated. Incubation with SOX9 produced a shifted band
(black arrow) that was supershifted by addition of the anti-SOX9 antibody (white arrow).
Incubation with nBmp2, however, produced no shifted band. Incubation of both SOX9
and nBmp2 with the enhancer produced the same DNA-protein complexes that formed
with SOX9 alone, indicating that nBmp2 does not bind to the M1/M2/D1/D2 enhancer.
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Figure 10. nBmp2 does not bind to the Col27a1 27(C/D/E) enhancer in
EMSA. The Col27a1 27(C/D/E) enhancer was radiolabeled by end-filling and incubated
with proteins as indicated. Incubation with SOX9 produced a shifted band (black arrow)
that was supershifted by addition of the anti-SOX9 antibody (white arrow). Incubation
with nBmp2, however, produced no shifted band. Incubation of both SOX9 and nBmp2
with the enhancer produced the same DNA-protein complexes that formed with SOX9
alone, indicating that nBmp2 does not bind to the 27(C/D/E) enhancer.
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Figure 11. nBmp2 does not bind to the Col27a1 F/G enhancers in EMSA.
The Col27a1 27(F/G) enhancer was radiolabeled by end-filling and incubated with
proteins as indicated. Incubation with SOX9 produced a shifted band (black arrow) that
was supershifted by inclusion of the anti-SOX9 antibody (white arrow). Incubation of
the enhancer sequence with nBmp2, however, produced no shifted band. Incubation of
both SOX9 and nBmp2 with the enhancer produced the same DNA-protein complexes
that formed with SOX9 alone, indicating that nBmp2 does not bind to the 27(F/G)
enhancer.
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